Targeted Silencing of Elongation Factor 2 Kinase Suppresses Growth and Sensitizes Tumors to Doxorubicin in an Orthotopic Model of Breast Cancer
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Eukaryotic elongation factor 2 kinase (eEF-2K), through its phosphorylation of elongation factor 2 (eEF2), provides a mechanism by which cells can control the rate of the elongation phase of protein synthesis. The activity of eEF-2K is increased in rapidly proliferating malignant cells, is inhibited during mitosis, and may contribute to the promotion of autophagy in response to anti-cancer therapies. The purpose of this study was to examine the therapeutic potential of targeting eEF-2K in breast cancer tumors. Through the systemic administration of liposomal eEF-2K siRNA (twice a week, i.v. 150 µg/kg), the expression of eEF-2K was down-regulated in vivo in an orthotopic xenograft mouse model of a highly aggressive triple negative MDA-MB-231 tumor. This targeting resulted in a substantial decrease in eEF2 phosphorylation in the tumors, and led to the inhibition of tumor growth, the induction of apoptosis and the sensitization of tumors to the chemotherapy agent doxorubicin. eEF-2K down-modulation in vitro resulted in a decrease in the expression of c-Myc and cyclin D1 with a concomitant increase in the expression of p27(Kip1). A decrease in the basal activity of c-Src (phospho-Tyr-416), focal adhesion kinase (phospho-Tyr-397), and Akt (phospho-Ser-473) was also detected following eEF-2K down-regulation in MDA-MB-231 cells, as determined by Western blotting. Where tested, similar results were seen in ER-positive MCF-7 cells. These effects were also accompanied by a decrease in the observed invasive phenotype of the MDA-MB-231 cells. These data support the notion that the disruption of eEF-2K expression in breast cancer cells results in the down-regulation of signaling pathways affecting growth, survival and resistance and has potential as a therapeutic approach for the treatment of breast cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Signalling to translation: How signal transduction pathways control the protein synthetic machinery
Proud, C. G. (2007) · Biochemical Journal · doi:10.1042/bj20070024 · Cited by 520 · cited 1×
“It has been suggested that progression through the G1-phase of the cell cycle and entry into the S phase (the G1/S transition) is promoted by eEF-2K activity [11], which is mediated by a rise in intracellular calcium (Ca) [12].”
BackgroundPark, S., Park, J. M., Kim, S., Kim, J.-A., Shepherd, J. D., Smith-Hicks, C. L., Chowdhury, S., Kaufmann, W., Kuhl, D., Ryazanov, A. G., et al. (2008) · Neuron · doi:10.1016/j.neuron.2008.05.023 · Cited by 516 · cited 2×
“Previously , it was suggested that the activation of eEF - 2K increases the expression of CaMK - II [ 63 ] and Arc [ 64 ] in neuronal cells , potentially by increasing CAP - dependent translation [ 65 ] .”
BackgroundBrowne, G. J., Finn, S. G., & Proud, C. G. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m309773200 · Cited by 353
Cited by
Long Noncoding RNA in Cancer: Wiring Signaling Circuitry
Lin, C., & Yang, L. (2018) · Trends in Cell Biology · doi:10.1016/j.tcb.2017.11.008 · Cited by 488
RNAi-based therapeutics and tumor targeted delivery in cancer
Kara, G., Calin, G. A., & Ozpolat, B. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114113 · Cited by 411
Self-citationLiu, R., & Proud, C. G. (2016) · Acta Pharmacologica Sinica · doi:10.1038/aps.2015.123 · Cited by 117
Karakas, D., & Ozpolat, B. (2020) · Journal of Molecular Medicine · doi:10.1007/s00109-020-01917-8 · Cited by 54
The Molecular Mechanism of Eukaryotic Elongation Factor 2 Kinase Activation
Tavares, C. D. J., Ferguson, S. B., Giles, D. H., Wang, Q., Wellmann, R. M., O'Brien, J. P., Warthaka, M., Brodbelt, J. S., Ren, P., & Dalby, K. N. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.577148 · Cited by 38
Self-citation
Metadata
- Authors
- Tekedereli, I., Alpay, S. N., Tavares, C. D. J., Cobanoglu, Z. E., Kaoud, T. S., Sahin, I., Sood, A. K., Lopez-Berestein, G., Dalby, K. N., & Ozpolat, B.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2012-07-20
- Volume
- 7
- Issue
- 7
- Pages
- e41171
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W1985917494
- Cited by
- 117
- References
- 3
- FWCI
- 3.02
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Targeted Silencing of Elongation Factor 2 Kinase Suppresses Growth and Sensitizes Tumors to Doxorubicin in an Orthotopic Model of Breast Cancer. https://app.cochat.ai/papers/10.1371/journal.pone.0041171
- The paper
- Tekedereli, I., Alpay, S. N., Tavares, C. D. J., Cobanoglu, Z. E., Kaoud, T. S., Sahin, I., Sood, A. K., Lopez-Berestein, G., Dalby, K. N., & Ozpolat, B. (2012). Targeted Silencing of Elongation Factor 2 Kinase Suppresses Growth and Sensitizes Tumors to Doxorubicin in an Orthotopic Model of Breast Cancer. PLoS ONE. https://doi.org/10.1371/journal.pone.0041171
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.